U.S. market Closed. Opens in 17 hours 4 minutes

GLUE | Monte Rosa Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue6.22M8.56M2.13M537.00K72.00K
Gross Profit-6.22M-8.56M-2.13M-537.00K-72.00K
Operating Expenses137.09M112.38M72.88M28.01M7.99M
Selling, General & Admin32.04M27.32M15.73M4.00M644.00K
Research & Development105.05M85.06M57.16M24.00M7.35M
Other Operating ExpensesN/AN/A-960.00K-7.68M276.00K
Operating Income-143.31M-112.38M-72.88M-28.01M-7.99M
Other Expenses / Income8.30M3.88M-1.08M-7.87M254.00K
Before Tax Income-135.01M-108.50M-73.96M-35.88M-7.74M
Income Tax Expenses338.00K-3.88M-2.02M189.00K277.00K
Net Income-135.35M-104.62M-71.94M-36.07M-8.02M
Interest ExpensesN/A3.76MN/AN/A1.00K
Basic Shares Outstanding51.40M47.23M46.54M44.00M44.00M
Diluted Shares Outstanding51.40M47.23M46.54M44.00M44.00M
EBITDA-137.09M-112.50M-72.72M-27.27M-7.65M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-135.01M-104.74M-73.96M-35.88M-7.74M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙